Roche stops development of Emugrobart
Dr. Lucienne Ronco, Chief Science Officer of the FSHD Society Originally published on March 19, 2026 Edited for clarity as of March 20, 2026 Today we received news that Roche […]
Dr. Lucienne Ronco, Chief Science Officer of the FSHD Society Originally published on March 19, 2026 Edited for clarity as of March 20, 2026 Today we received news that Roche […]
Dear members of the FSHD community, Following your request for updates about our FSHD clinical development programme, today I share the news that we have made the difficult decision not […]
By Selina Lai, MS, Nutritionist In the past year there have been 2 investigative surveys of the lead content of protein powder supplements published by The Clean Label Project1 and […]
Press release originally posted to the MDA website on Jan. 27, 2026 Organizations Join Forces to Map How Human Muscle Regenerates Muscular Dystrophy Association-led research collaboration with FSHD Society, LGMD2L […]
January 12, 2026, Originally posted to Business Wire Highlights: Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children […]